Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

On November 7, 2011, the U.S. Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approval was based on a randomized stud...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Cohen, Martin H., Chen, Huanyu, Shord, Stacy, Fuchs, Chana, He, Kun, Zhao, Hong, Sickafuse, Sharon, Keegan, Patricia, Pazdur, Richard
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2013
Soggetti:
Regulatory Issues: FDA
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639534/
https://ncbi.nlm.nih.gov/pubmed/23576486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0458
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi